ArticleResearch and practice in thrombosis and haemostasis2025
Evaluation of a new commercial assay for the measurement of tissue factor activity of extracellular vesicles isolated from human plasma.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating extracellular vesicle tissue factor activity is associated with disseminated intravascular coagulation in 2 cohorts of patients with sepsis.Research and practice in thrombosis and haemostasis · 2026Article
- Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tissue factor (TF)-positive extracellular vesicles (EVs) are released into the circulation and activate coagulation in several diseases, such as sepsis, viral infections, and cancer. Objectives: We compared a new commercial assay, called "CY-QUANT MV-TF" (CY), with an in-house assay (Chapel Hill [CH]) for the measurement of EV TF activity. Methods: TF-positive EVs were generated by stimulating citrated human whole blood from 4 healthy donors with lipopolysaccharide for 5 hours. EVs were isolated from platelet-low plasma by centrifugation at 20,000 × Results: Lower levels of EV TF activity were detected in the samples using the CY assay compared with the CH assay (mean ± SD, 0.54 ± 0.30 pg/mL, Conclusion: In this study, we found that the CY assay detected TF activity in EVs isolated from plasma. However, significant amounts of TFPI were present in the EV preparations using the CY EV isolation protocol, which inhibited TF activity, leading to lower apparent EV TF levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.